Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OMT 28

Drug Profile

OMT 28

Alternative Names: 17,18-epoxyeicosatetraenoic acid analog; OMT-28

Latest Information Update: 30 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OMEICOS Therapeutics
  • Class Antiarrhythmics; Cardiovascular therapies; Eicosanoids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Nitric oxide stimulants; Peroxisome proliferator-activated receptor alpha agonists; Phosphatidylinositol 3 kinase gamma modulators; Protein kinase stimulants; Proto oncogene protein c akt modulators; Sirtuin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Atrial fibrillation
  • Preclinical Myocardial infarction

Most Recent Events

  • 03 Jan 2019 Phase-II clinical trials in Atrial fibrillation in Czech Republic (PO) after January 2019 (EudraCT2018-001626-26)
  • 03 Jan 2019 Phase-II clinical trials in Atrial fibrillation in Hungary (PO) (EudraCT2018-001626-26)
  • 27 Apr 2018 OMEICOS Therapeutics plans a phase II trial for Atrial fibrillation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top